Evidence depth: moderate · Moderate public-data fit

Pathology

The ultimate 'doctor's doctor'. A purely cognitive, entirely non-patient-facing specialty focused on diagnostic accuracy at the microscope. The lane (general AP/CP, dermatopathology, or forensic) decides income, ownership, and lifestyle.

Build Your Report RVU calculator All specialties

Where to start

Best-fit Pathology paths

Directional, modeled. Your priorities decide. Build a report to make it yours.

If you want the highest income

Dermatopathology

High; one of the best-paid path lanes.

$410k - $525k

See this path →

If you want the best lifestyle

Anatomic / Clinical

Solid.

$330k - $420k

See this path →

If you want ownership upside

Forensic Pathology

Lower; public-sector pay scales.

$280k - $355k

See this path →

Data Highlights

Specialty Insights

Public data · NPPES20,648 clinicians in the NPI registry roster. Registration, not verified active practiceTop states: CA, TX, NYAggregate workforce/geography, not income.

Competitiveness context: moderate - NRMP 2024

700 positions offeredmoderate applicants-per-position tierNRMP 2024 Main Residency Match published specialty tables

Modeled Paths: 3
Top Modeled Ceiling: $500k - $750k (If Lab Partner)
Best Lifestyle Path: Anatomic / Clinical
Highest Equity Upside: Dermatopathology

Public data · CMS Medicare Part B

What this specialty actually bills Medicare

Internal. Mostly cognitive / cash-pay, low Medicare procedure signal

Aggregate allowed amount: $1.1B; Medicare Part B, not income
Providers in panel: 20,645; NPPES individual NPIs
NPI → Medicare join: 51%; billed Medicare in the year
Open Payments physicians: 3,239; transfers of value, not income

Top procedures by Medicare allowed-$ (public CMS data)

G0416 · Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method$23M
36415 · Insertion of needle into vein for collection of blood sample$8M
G0452 · Molecular pathology procedure; physician interpretation and report$4M
G0181 · Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow$2M
G0145 · Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision$1M

Source: CMS Medicare Physician & Other Practitioners (public). This is not W-2 salary, total collections, or take-home income. Aggregate allowed amounts are a partial, biased slice of one payer; sector labels are keyword-inferred from public procedure descriptions and are directional, pending physician review.

Paths

Path families to test

Anatomic / Clinical

Solid.

External benchmark reference: ~$380k

DoctorCalculator modeled estimate: Ceiling: $450k - $600k (If Lab Partner)

View path →

Dermatopathology

High; one of the best-paid path lanes.

External benchmark reference: ~$470k

DoctorCalculator modeled estimate: Ceiling: $500k - $750k (If Lab Partner)

View path →

Forensic Pathology

Lower; public-sector pay scales.

External benchmark reference: ~$220k

DoctorCalculator modeled estimatePremium

View path →

Path Landscape

Compare all 3 paths

Premium tool

Unlock 10-dimension comparison matrix

See exactly how every path stacks up across lifestyle, sleep, ownership, and income.

Unlock premium

Path battle card

Compare head-to-head

Path A

Path B

Pathology

Anatomic / Clinical

Really about: high-accuracy, non-patient-facing diagnostic interpretation

validated confidence

Pathology

Dermatopathology

Really about: high-margin, lifestyle-friendly subspecialty diagnostic reading

directional confidence

1. Income ceilingedge → Dermatopathology: Mixed
Solid, but heavily volume-dependent and threatened by consolidation.
The reality · The signal · The catch · The verdict
The reality: If you are an employee, you are paid strictly for the volume of slides you can safely read.
The signal: If you make partner in an independent lab, you capture the highly lucrative technical fee for processing the tissue.
The catch: However, the mega-labs have crushed many independent practices, capping the ceiling for new grads.
The verdict: A very comfortable living, but true wealth requires lab equity.; Favorable
Among the highest in pathology, driven by biopsy throughput.
The reality · The signal · The catch · The verdict
The reality: High-volume skin biopsies are read efficiently and reimbursed well per specimen.
The signal: Capturing the technical fee in-group, rather than sending it out, multiplies the economics.
The catch: Reimbursement for routine biopsies has softened over time, gently pressuring the ceiling.
The verdict: A top-tier pathology income if you control the lab and the referral volume.
2. Lifestyle control: Favorable
Exceptional control; highly predictable hours.
The reality · The signal · The catch · The verdict
The reality: The tissue does not complain, and the slides do not page you.
The signal: You work a highly structured, predictable day (e.g., 8 AM to 5 PM).
The catch: When you leave the lab, you are completely done.
The verdict: An absolute gold standard for physicians who want to leave work at work.; Favorable
Excellent; a predictable outpatient reading rhythm.
The reality · The signal · The catch · The verdict
The reality: Slides queue and are read on your schedule, with no emergencies to interrupt.
The signal: The workflow mirrors a controllable outpatient practice more than a hospital service.
The catch: You leave the work at the scope when the day ends.
The verdict: One of the most lifestyle-protective niches in all of medicine.
3. Sleep / call burden: Favorable
Effectively zero.
The reality · The signal · The catch · The verdict
The reality: There are virtually no overnight pathology emergencies.
The signal: Clinical pathology call (blood bank issues) can happen, but is exceedingly rare and handled over the phone.
The catch: You will sleep in your own bed every single night.
The verdict: Perfect for those requiring protected sleep.; Favorable
Effectively zero.
The reality · The signal · The catch · The verdict
The reality: Dermatopathology has no overnight emergencies and no meaningful call.
The signal: Any urgent question is handled during business hours.
The catch: You sleep in your own bed every night of your career.
The verdict: Ideal for anyone who requires fully protected sleep.
4. Ownership / facility upsideedge → Dermatopathology: Mixed
Strong, but the barrier to entry is massive.
The reality · The signal · The catch · The verdict
The reality: True pathology wealth comes from owning the independent reference lab and capturing the technical fees.
The signal: However, competing with LabCorp and Quest for hospital contracts is brutally difficult.
The catch: Most new grads will be W-2 employees without equity.
The verdict: A fantastic owner-operator play if you can secure the contracts, but highly risky.; Favorable
Strong, when the lab and technical fee sit in-group.
The reality · The signal · The catch · The verdict
The reality: Owning the processing lab captures the lucrative technical component of each biopsy.
The signal: Derm-owned or pathologist-owned labs build genuine, sellable enterprise value.
The catch: The upside collapses if a large derm group controls your slide volume and outsources processing.
The verdict: A real owner-operator play. Provided you own the referral relationship, not just the read.
5. Geography flexibilityedge → Anatomic / Clinical: Favorable
Good, but concentrated in larger hospital systems or national labs.
The reality · The signal · The catch · The verdict
The reality: You do not need to build a patient referral base.
The signal: However, a small rural hospital may only need one part-time pathologist, limiting options.
The catch: You must go where the high-volume surgical centers or national reference labs are located.
The verdict: Provides solid, but not infinite, geographic freedom.; Mixed
Metro-weighted and tethered to dermatology referrals.
The reality · The signal · The catch · The verdict
The reality: Your volume comes from nearby dermatology practices, which concentrate in populated areas.
The signal: You cannot generate cases independently the way a clinician builds a panel.
The catch: Rural markets rarely produce enough biopsy volume to support a dedicated dermatopathologist.
The verdict: Solid within metros, constrained if you are fixed to a small or rural market.
6. Innovation / industry adjacencyedge → Anatomic / Clinical: Favorable
Very high, sitting at the forefront of AI and digital medicine.
The reality · The signal · The catch · The verdict
The reality: Digital pathology (scanning slides) and AI-assisted diagnosis are fundamentally transforming the field.
The signal: Massive consulting potential for health-tech startups developing diagnostic algorithms.
The catch: Molecular pathology and genetic sequencing are the future of personalized oncology.
The verdict: An intellectually thrilling path for the tech-forward physician.; Mixed
Moderate; digital and molecular dermpath are advancing.
The reality · The signal · The catch · The verdict
The reality: Whole-slide imaging and AI-assisted screening are entering high-volume biopsy workflows.
The signal: Molecular assays for melanoma and inflammatory disease add a growing diagnostic layer.
The catch: The day-to-day remains high-throughput routine reading rather than frontier research.
The verdict: A meaningful but secondary technology adjacency for the interested.
7. Training opportunity cost: Mixed
Requires a 4-year residency plus 1-2 years of fellowship.
The reality · The signal · The catch · The verdict
The reality: Almost all pathologists do at least one fellowship (e.g., GI, Dermpath, Hematopathology) to be competitive.
The signal: A reasonable 5-6 year training path.
The catch: The hours during residency are generally humane compared to surgery.
The verdict: A fair financial ROI for the lifestyle achieved.; Mixed
A single, competitive fellowship year.
The reality · The signal · The catch · The verdict
The reality: You add one dermatopathology fellowship after pathology (or dermatology) residency.
The signal: The fellowship is competitive precisely because the lifestyle-to-income ratio is so favorable.
The catch: The marginal time cost is small relative to the earnings and lifestyle it unlocks.
The verdict: An efficient, high-ROI subspecialization.
8. Job-market density: Mixed
Moderate; highly dependent on subspecialty and location.
The reality · The signal · The catch · The verdict
The reality: The market is heavily consolidated.
The signal: Dermatopathology and GI pathology are highly sought after by lucrative private groups.
The catch: General pathology jobs exist, but you may have less leverage against the corporate mega-labs.
The verdict: A stable market, but requires strategic fellowship choices.; Mixed
Sought-after, but gated by referral relationships.
The reality · The signal · The catch · The verdict
The reality: Lucrative private groups actively recruit dermatopathologists.
The signal: The best roles depend on access to a stable, high-volume derm referral pipeline.
The catch: Whoever controls that pipeline holds the leverage, which may not be you.
The verdict: A good market for the credential, with the caveat that volume control decides its value.
9. Malpractice / litigation pressure: Mixed
Moderate; entirely focused on the 'missed diagnosis'.
The reality · The signal · The catch · The verdict
The reality: Missing a melanoma or a subtle breast cancer on a slide is the classic, devastating lawsuit.
The signal: You do not face the angry patient, but your signature is on the definitive cancer diagnosis.
The catch: Requires extreme meticulousness and a refusal to rush complex cases.
The verdict: A manageable risk profile for a detail-oriented personality.; Mixed
Moderate; the missed melanoma is the defining risk.
The reality · The signal · The catch · The verdict
The reality: Under- or over-calling a pigmented lesion is the classic, high-consequence error.
The signal: Your signature is the definitive diagnosis that drives a patient's cancer care.
The catch: High volume raises the sheer number of specimens where a miss could occur.
The verdict: Manageable with meticulous technique, but the melanoma tail keeps it above general path.
10. Burnout-mismatch risk: Favorable
Low risk for introverts who thrive on intense visual focus.
The reality · The signal · The catch · The verdict
The reality: If you need patient interaction, clinical gratitude, or the adrenaline of the ER, you will be deeply miserable.
The signal: Requires the ability to sit at a microscope in silence for 8 hours a day.
The catch: An absolutely excellent fit for cognitive purists and lifestyle-seekers.
The verdict: Low mismatch risk if you accept the isolated nature of the work.; Favorable
Low, with a dependency-related caveat.
The reality · The signal · The catch · The verdict
The reality: The isolated, high-focus microscope work suits cognitive introverts extremely well.
The signal: The zero-call, predictable lifestyle is a durable satisfaction driver.
The catch: The real stressor is becoming captive to one large derm group that controls your volume.
The verdict: A superb fit for lifestyle-first pathologists who secure their own referral independence.
11. What people regret: • Realizing you are treated as a commodity 'read generator' by a corporate mega-lab that tracks your slides-per-hour metrics.
• Missing the human connection and gratitude of actual patient care.; • Becoming dependent on one large dermatology group that controls your entire slide volume.
• Watching reimbursement for routine skin biopsies decline over time.
12. Best-fit archetypes: Lifestyle-First Clinician; Lifestyle-First Clinician, Owner-Operator Physician
13. Poor-fit archetypes: Acute-Care Identity Seeker; Acute-Care Identity Seeker
14. Questions to ask mentors / fellowships / jobs: • Does this group own an independent reference lab, or do they just contract to read for the local hospital?
• What is the daily slide volume expectation, and is it primarily complex oncology or routine GI/Derm biopsies?
• Has the group been approached by private equity, and is the partnership track genuine?; • Who controls the referral slide volume. You or the derm group?
• Is the technical fee captured in-group or sent out?

Evidence & reveals

Clinician assumptionvalidated

Pathology income hinges on lab equity, not the read itself.

Why · signal · limit · impact

Why: An employed pathologist and a lab partner with the same workload can earn 2x apart.

Signal: Heavy PE roll-up of independent labs has compressed new-graduate equity (NPPES lists ~20,000 US pathologists).

Caveat: Technical-fee capture and partnership terms are opaque and vary widely.

Impact: Verify whether the partnership track is genuine and whether the group owns the lab.

Clinician assumptiondirectional

Dermatopathology is the highest-margin, most lifestyle-friendly pathology lane.

Why · signal · limit · impact

Why: It pairs zero call with strong technical-fee economics if you control the lab.

Signal: Demand driven by high-volume skin-biopsy throughput from dermatology referrals.

Caveat: Volume control sits with whoever owns the derm referral relationship.

Impact: Verify who owns the referral pipeline and technical fee before ranking.

Scores are relative, directional signals, not dollars and never a salary claim. Each carries its own why, supporting signal, limitation, and decision impact, and the confidence badge shows how validated each path is.

Field notes

Private equity has heavily targeted independent pathology labs, rolling them up into national mega-labs (Quest, LabCorp) and stripping the equity upside from many new graduates.

Questions to ask

Where did recent graduates land, and at what real compensation model?
What's the realistic path to ownership or production upside?

Run your personalized report

Premium turns your target life into a required-income number, then tests it against these paths for salary-only gap, ownership upside, call burden, and geography. Evidence depth and confidence stay visible inside every report.

Build Your Report